The study by Riley et al., despite its retrospective design, represents the largest dataset to date, offering robust evidence on cardiovascular and renal outcomes associated with this therapeutic strategy (106)
Start your Wegovy consultation today
Phase 3 readouts have since pushed even higher in some populations
Figure 28: Photograph of the gastrointestinal researchers at Bispebjerg Hospital in 1975, credit: Figure 1.3.3, Holst 2024
Its also advisable not to consume alcohol excessively, as it may increase the risk of pancreatitis
Clinical trial data on Retatrutides benefits is striking: Weight loss up to 24% of total body weight within 48 weeks outpacing both semaglutide and tirzepatide in head-to-head comparisons 3050% reduction in appetite , making dietary adherence significantly easier Visceral fat reduction of up to 40%, targeting the most metabolically harmful fat stored around organs Improved glycemic control and reduced insulin resistance, with benefits for those at risk of or managing type 2 diabetes Liver health improvement emerging data suggests positive effects on non-alcoholic fatty liver disease (NAFLD) Elevated resting energy expenditure , meaning your body burns more calories at rest For residents of Dubai pursuing sustainable, medically supervised weight management, these outcomes represent a meaningful leap forward
:max_bytes(150000):strip_icc()/Health-GettyImages-1675158771-70640c9fdf1b41078975cfc3fd538a6b.jpg)
